GM-CSF targeting in COVID-19: an approach based on fragile foundations.
Published version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Kohler, Katharina
Conway Morris, Andrew https://orcid.org/0000-0002-3211-3216
Abstract
Trials of anti-GM-CSF therapies in COVID-19 show divergent results; this may be explained by underlying biology and the fragility of the study findings. Further investigation of the pathophysiology of COVID-19 is required to better target therapies. http://bit.ly/3O1AuIo
Description
Keywords
Humans, COVID-19, Antibodies, Monoclonal, Humanized
Is Part Of
Publisher
European Respiratory Society (ERS)
Publisher DOI
Sponsorship
MRC (MR/V006118/1)
Academy of Medical Sciences (SGL023\1048)
Academy of Medical Sciences (SGL023\1048)
KK is supported by grants from the Academy of Medical Sciences (SG023\1048) and NIHR Development and Skills Enhancement award (NIHR 302841). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. ACM is supported by a Clinician Scientist Fellowship from the Medical Research Council (MR/V006118/1).